Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 76

Sort by

Sort Order Select

Journal Articles

Structural Basis of Vitamin K Antagonism

Weikai Li, PhD, Shixuan Liu, Shuang Li

Blood (2019) 134 (Supplement_1): 482.

https://doi.org/10.1182/blood-2019-127324

Published: 2019

Journal Articles

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

Philip A. Thompson, MBBS, Michael J Keating, MBBS, Nitin Jain, MD, Alessandra Ferrajoli, MD, Tapan M. Kadia, MD, Prithviraj Bose, MD, William G. Wierda, MD PhD

Blood (2019) 134 (Supplement_1): 358.

https://doi.org/10.1182/blood-2019-129230

Published: 2019

Journal Articles

Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

John McKay, DO, Taha Al-Juhaishi, MD, Lai Guanhua, MD PhD, Maciej Kmieciak, PhD, Roy Sabo, PhD, Ariel Sindel, DO, Victor Yazbeck, MD

Blood (2019) 134 (Supplement_1): 5482.

https://doi.org/10.1182/blood-2019-126335

Published: 2019

Journal Articles

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Ulrich Jaeger, MD, Nina Worel, MD, Joseph P. McGuirk, DO, Peter A. Riedell, MD, Isabelle Fleury, MD, Peter Borchmann, MD, Jufen Chu, PhD, Ahmed M Abdelhady, PhD, Alessandra Forcina, MD, Lida Bubuteishvili Pacaud, MD, Edmund K. Waller, PhDMD

Blood (2019) 134 (Supplement_1): 5325.

https://doi.org/10.1182/blood-2019-129120

Published: 2019

Journal Articles

A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours

Jean-Pierre Delord, MD, Nuria Kotecki, MD, Aurelien Marabelle, MD PhD, Armelle Vinceneux, MD, Iphigenie Korakis, MD, Christiane Jungels, MD, Stéphane Champiat, MD, Richard D. Huhn, MD, Nicolas Poirier, PhD, Dominique Costantini, MD, Bérangère Vasseur, MD, Philippe A. Cassier, MD

Blood (2019) 134 (Supplement_1): 1040.

https://doi.org/10.1182/blood-2019-124876

Published: 2019

Journal Articles

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study

Scott F. Huntington, MD MPH, Avyakta Kallam, MD, Frank G. Basile, MD, Danielle Ulanet, Huansheng Xu, PhD, Feng Yin, PhD, Michelle Mobilia, BS, Michael Cooper, MD, Bijal Shah, MD, John P. Leonard, MD, Gottfried R. von Keudell, MD PhD, Ajay K. Gopal, MD

Blood (2019) 134 (Supplement_1): 1286.

https://doi.org/10.1182/blood-2019-123420

Published: 2019

Journal Articles

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Martin Hutchings, MD PhD, Giuseppe Gritti, MD PhD, Anna Sureda, MD PhD, Maria Jose Terol, Martin JS Dyer, DPhil, Gloria Iacoboni, MD, William Townsend, MRCP,MDFRCPath, Marina Bacac, PhD, Ann-Marie E Bröske, PhD, Natalie Dimier, PhD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Angelika Lahr, PhD, Katharina Lechner, MD, Tom Moore, MBChB, Peter N Morcos, PharmD, Anesh Panchal, MSc, Martin Weisser, MD, Ciel De Vriendt

Blood (2019) 134 (Supplement_1): 2871.

https://doi.org/10.1182/blood-2019-123978

Published: 2019

Journal Articles

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

Dirk Reinhardt, MD, Christian Michel Zwaan, Albert Hoenekopp, Julie Niolat, Sophie Ifrah, Florence Noel-Baron, Franco Locatelli, MD

Blood (2019) 134 (Supplement_1): 3835.

https://doi.org/10.1182/blood-2019-128043

Published: 2019

Journal Articles

NUDT15 Variants Confer High Incidence of Secondary Malignancies of ALL in Children

Blood (2019) 134 (Supplement_1): 2751.

https://doi.org/10.1182/blood-2019-125713

Published: 2019

Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD

Blood (2019) 134 (Supplement_1): 1867.

https://doi.org/10.1182/blood-2019-125629

Published: 2019

Journal Articles

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

Franck Morschhauser, MD, Carmelo Carlo-Stella, MD, Fritz Offner, MD, Gilles A. Salles, MD PhD, Martin Hutchings, MD PhD, Gloria Iacoboni, MD, Anna Sureda, MD PhD, Michael Crump, MD, Joaquin Martinez-Lopez, MD PhD, Denise Thomas, MSc, Peter N Morcos, PharmD, Cristiano Ferlini, MD, Abiraj Keelara, PhD, Ann-Marie E Bröske, PhD, Marina Bacac, PhD, Natalie Dimier, PhD, Tom Moore, MBChB, Martin Weisser, MD, Michael Dickinson, MBBS,FRACP,FRCPA

Blood (2019) 134 (Supplement_1): 1584.

https://doi.org/10.1182/blood-2019-123949

Published: 2019

Journal Articles

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Sarit Assouline, MD, Amitkumar Mehta, MD, Paolo F Caimi, MD, Bingxia Wang, PhD, Chirag Patel, Mi-Sook Kim, Dennis Huszar, Allison J Berger, PhD, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim

Blood (2019) 134 (Supplement_1): 1593.

https://doi.org/10.1182/blood-2019-128773

Published: 2019

Journal Articles

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

Naveen Pemmaraju, MD, Uma Borate, MD, Melhem Solh, MD, Gautam M. Borthakur, MD, Amy E. DeZern, MD, Chao Zhang, PhD, Ben Powell, PhD, Paul Severson, Kerry Inokuchi, Bernice Matusow, Jason Halladay, Ching Hsu, PhD, Paul Watkins, Jackie M. Walling, PhD MD, Athanasios C. Tsiatis, MD, Alice S. Mims, MD

Blood (2019) 134 (Supplement_1): 1391.

https://doi.org/10.1182/blood-2019-127497

Published: 2019

Journal Articles

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Naval G. Daver, MD, Weiguo Zhang, MD PhD, Richard Graydon, MD PhD, Vikas K Dawra, MBA, PhD, Jingdong Xie, PhD, Prasanna Kumar, PhD, Michael Andreeff, MD PhD

Blood (2019) 134 (Supplement_1): 1389.

https://doi.org/10.1182/blood-2019-122585

Published: 2019

Journal Articles

Prevalence and Risk Factors for Opioid-Related Complications in Patients with Myeloproliferative Neoplasms: An International Survey of 502 Patients By the MPN Quality of Life Study Group

Holly L. Geyer, MD, Robyn M. Scherber, MD MPH, Gina Mazza, PhD, Blake Langlais, Leslie Padrnos, MD, Jeanne Palmer, MD, Amylou C. Dueck, PhD, Ruben A. Mesa, MD

Blood (2018) 132 (Supplement 1): 4297.

https://doi.org/10.1182/blood-2018-99-115143

Published: 2018

Journal Articles

Hypofibrinogenemia in Patient with Extended Exposure to Argatroban Therapy

Mustafa Saudi, MD

Blood (2018) 132 (Supplement 1): 5035.

https://doi.org/10.1182/blood-2018-99-117765

Published: 2018

Journal Articles

Monitoring the Effects of Direct Oral Anticoagulants with a Novel Point-of-Care Sensor: Results of a Pilot Clinical Study

Aman Opneja, MBBS, Debnath Maji, M.Tech, Pedram Mohseni, PhD, Michael A Suster, PhD, Evi X Stavrou, MD

Blood (2018) 132 (Supplement 1): 988.

https://doi.org/10.1182/blood-2018-99-118943

Published: 2018

Journal Articles

Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine

Mandy David, PA-C, MPH, Christopher Carroll, MD, Ashley Lauriello, NP, Benjamin Salzberg, Sophie Lanzkron, MD MHS

Blood (2018) 132 (Supplement 1): 856.

https://doi.org/10.1182/blood-2018-99-111435

Published: 2018

Journal Articles

Clinical Characteristics and Health Care Utilization Patterns of Sickle Cell Disease Patients Using Marijuana

Hope Miodownik, BA, Christopher Bradford, BA, Joanna L. Starrels, MD MS, Ugochi Olivia Ogu, MD, Merin Thomas, NP, Chinazo O. Cunningham, MD MS, Julia H. Arnsten, MD MPH, Caterina Minniti, MD

Blood (2018) 132 (Supplement 1): 3669.

https://doi.org/10.1182/blood-2018-99-118163

Published: 2018

Journal Articles

Opioid Dependency Significantly Increases Complications and Mortality in Sickle Cell Disease

Stuthi Pavani Perimbeti, MD MPH, Kevin Ye Hou, MD, Sabarina Ramanathan, MD, Adonas Woodard, MD, Daniel Kyung, MD, Priyadarshini Pathak, MBBS, Rishi Shrivastav, MD, Kristine Ward, MD, Michael Styler, MD

Blood (2018) 132 (Supplement 1): 4701.

https://doi.org/10.1182/blood-2018-99-120012

Published: 2018

NARROW

Structural Basis of Vitamin K Antagonism

Venetoclax Added to Ibrutinib in High-Risk CLL Achieves a High Rate of Undetectable Minimal Residual Disease. [RTS1]

Rive-CLL: Phase 1 Trial of Rituximab, Idelalisib, and Venetoclax in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia

Portia: A Phase 1b Study Evaluating Safety and Efficacy of Tisagenlecleucel and Pembrolizumab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

A Phase 1 Study Evaluating BI 765063, a First in Class Selective Myeloid Sirpa Inhibitor, As Stand-Alone and in Combination with BI 754091, a Programmed Death-1 (PD-1) Inhibitor, in Patients with Advanced Solid Tumours

AG-636 for the Treatment of Adults with Advanced Lymphoma: Initiation of a Phase 1 Clinical Study

CD20-TCB, a Novel T-Cell-Engaging Bispecific Antibody, Can be Safely Combined with the Anti-PD-L1 Antibody Atezolizumab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Phase II Study of Midostaurin + Chemotherapy in Pediatric Patients with Untreated, Newly Diagnosed, FLT3 -Mutated Acute Myeloid Leukemia (AML)

NUDT15 Variants Confer High Incidence of Secondary Malignancies of ALL in Children

Dual CD20-Targeted Therapy With Concurrent CD20-TCB and Obinutuzumab Shows Highly Promising Clinical Activity and Manageable Safety in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Preliminary Results From a Phase Ib Trial

A Phase 1b/2 Study of TAK-981, a First-in-Class Sumoylation Inhibitor, in Combination with Rituximab in Patients with Relapsed/Refractory (r/r) CD20-Positive Non-Hodgkin Lymphoma (NHL)

Dose Escalation Study of BET Inhibitor PLX2853 in Patients with Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

A Phase 1 Study of Milademetan in Combination with Quizartinib in Patients with Newly Diagnosed (ND) or Relapsed/Refractory (R/R) FLT3 -ITD Acute Myeloid Leukemia (AML)

Prevalence and Risk Factors for Opioid-Related Complications in Patients with Myeloproliferative Neoplasms: An International Survey of 502 Patients By the MPN Quality of Life Study Group

Hypofibrinogenemia in Patient with Extended Exposure to Argatroban Therapy

Monitoring the Effects of Direct Oral Anticoagulants with a Novel Point-of-Care Sensor: Results of a Pilot Clinical Study

Assessing the Safety and Efficacy of Converting Adults with Sickle Cell Disease from Full Agonist Opioids to Buprenorphine

Clinical Characteristics and Health Care Utilization Patterns of Sickle Cell Disease Patients Using Marijuana

Opioid Dependency Significantly Increases Complications and Mortality in Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only